ImmunityBio, Inc. is a biotech company developing new medicines.
ImmunityBio, Inc. (IBRX) is expected to report earnings on Tuesday, November 3, 2026, before the open. Estimated release time 07:34 ET. Consensus EPS estimate is $-0.07.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | Jun 2026 qtr | $-0.08 | $-0.22 | — | $51.24M |
| 2026-05-07 | Mar 2026 qtr | $-0.08 | $-0.62 | — | $44.21M |
| 2026-02-23 | Dec 2025 qtr | $-0.08 | $-0.06 | — | $38.28M |
| 2025-11-05 | Sep 2025 qtr | $-0.10 | $-0.07 | — | $32.06M |
| 2025-08-05 | Jun 2025 qtr | $-0.10 | $-0.10 | +0.0% | $26.43M |
| 2025-05-12 | Mar 2025 qtr | $-0.12 | $-0.15 | — | $16.52M |
| 2025-03-03 | Dec 2024 qtr | $-0.26 | $-0.08 | — | $7.55M |
| 2024-11-12 | Sep 2024 qtr | $-0.18 | $-0.12 | — | $6.11M |
IBRX has beaten consensus EPS in 1 of its last 1 scored quarters.
See IBRX on the live calendar →